DiagnaMed Opens Enrollment For Healthcare Provider Network For Brain Health Platform
DiagnaMed Holdings (CSE: DMED) is moving forward with the commercialization of CERVAI, its brain health AI platform.
Read moreDiagnaMed Holdings (CSE: DMED) is moving forward with the commercialization of CERVAI, its brain health AI platform.
Read moreDiagnaMed Holdings (CSE: DMED) is anticipating to begin the commercialization stage of its flagship CERVAI brain health AI platform in the fourth quarter of 2023.
Read moreDiagnaMed Holdings (CSE: DMED) is expected to begin the deployment of its brain age estimation tool known as CERVAI to third party sites in the fourth quarter of 2023.
Read moreDiagnaMed Holdings (CSE: DMED) has launched its third generative AI product to the marketplace.
Read moreFULL DISCLOSURE: This is sponsored content for DiagnaMed Holdings. A new division has been established by DiagnaMed Holdings (CSE: DMED) to
Read moreDiagnaMed Holdings (CSE: DMED) has launched its first commercial product under its initiative to bring artificial intelligence to the healthcare industry. The initiative is currently focused on using AI to improve patient outcomes, operational workflow, and efficiency within the industry.
Read moreJoining us today on the Daily Dive is that of DiagnaMed Holdings (CSE: DMED) Chairman Fabio Chianelli, and Dr. John
Read moreDiagnaMed Holdings (CSE: DMED) is moving to enhance its brain health artificial intelligence platform known as CERVAI. The company has
Read moreDiagnaMed Holdings (CSE: DMED) appears to be going all in on artificial intelligence. The drug development firm this morning revealed
Read moreDiagnaMed Holdings (CSE: DMED) is moving towards obtaining regulatory approval for its Brain Age clinical solution by the end of
Read more